Vitrakvi

Chemical Namelarotrectinib
Dosage FormCapsule (oral; 25 mg, 100 mg) Oral Solution (oral; 20 mg/mL)
Drug ClassKinase inhibitors
SystemOther
CompanyBayer HealthCare Pharmaceuticals Inc.
Approval Year2018

Indication

  • To treat metastatic solid tumors or tumors without the possibility of surgical resection that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation that have either progressed following treatment or are in patients with no alternative treatments.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vitrakvi (Larotrectinib) Prescribing Information 2018Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
Document TitleYearSource
Metastatic pancreatic cancer: ASCO guideline update. 2020Journal of Clinical Oncology